NeuroPace (NASDAQ:NPCE) Trading Up 4% – Should You Buy?

NeuroPace, Inc. (NASDAQ:NPCE) shares traded up 4% during mid-day trading on Monday . The company traded as high as $11.65 and last traded at $11.47. 79,703 shares were traded during mid-day trading, a decline of 17% from the average session volume of 95,657 shares. The stock had previously closed at $11.03.

Analyst Ratings Changes

Separately, Wells Fargo & Company dropped their target price on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, NeuroPace has a consensus rating of “Moderate Buy” and an average target price of $14.60.

NeuroPace Stock Performance

The business has a 50 day moving average price of $8.42 and a 200 day moving average price of $7.59. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock has a market capitalization of $342.36 million, a PE ratio of -11.47 and a beta of 2.05.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. The business had revenue of $21.06 million during the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period last year, the business earned ($0.28) EPS. As a group, equities research analysts expect that NeuroPace, Inc. will post -1 earnings per share for the current year.

Insider Buying and Selling at NeuroPace

In other news, major shareholder Ltd. Kck sold 4,910 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60. Following the sale, the insider now owns 5,540,104 shares of the company’s stock, valued at $36,897,092.64. This trade represents a 0.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders have sold 257,590 shares of company stock worth $1,437,916. Insiders own 22.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in shares of NeuroPace during the 2nd quarter valued at $257,000. Financial Advocates Investment Management lifted its holdings in NeuroPace by 50.0% in the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after acquiring an additional 5,000 shares during the period. Rhumbline Advisers purchased a new position in NeuroPace in the second quarter worth about $111,000. Acadian Asset Management LLC grew its stake in shares of NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after purchasing an additional 21,703 shares during the period. Finally, XTX Topco Ltd increased its position in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.